A phase I, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of single‑ and multiple‑ascending oral doses of RO7440688, the effect of food on the pharmacokinetics of RO7440688, and the effects of RO7440688 on midazolam pharmacokinetics in healthy volunteers
Latest Information Update: 27 Jul 2022
At a glance
- Drugs RO 744068 (Primary) ; Midazolam
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Genentech
- 22 Jul 2022 Planned End Date changed from 1 Mar 2022 to 21 Mar 2022.
- 03 Mar 2022 Status changed from active, no longer recruiting to completed.
- 22 Feb 2022 Status changed from recruiting to active, no longer recruiting.